Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenosine monotungstate is an experimental small molecule compound formed by the combination of adenosine—a purine nucleoside involved in cellular metabolism and signaling—and a tungsten atom. Its chemical formula is C10H15N5O7W and it has a molecular weight of approximately 501 g/mol[1][2][5]. The incorporation of tungsten into the adenosine structure may enhance its biological activity and stability compared to traditional nucleosides. Adenosine monotungstate has been investigated for potential therapeutic applications in antiviral and anticancer treatments[4]. It acts as an inhibitor of bis(5'-adenosyl)-triphosphatase in humans; however, its precise pharmacological action remains under investigation[1]. Research on this compound is ongoing to better understand its interactions with biological systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adenosine monotungstate.